Risk of Infections in Patients Using Anti-TNF Medications: A Literature Review
DOI:
https://doi.org/10.56570/jimgs.v1i2.38Keywords:
Autoimmune Rheumatic Disorders (ARDs), bDMARDs (biologic DMARDs), Infection risk, Rheumatoid Arthritis (RA), TNF inhibitors & vaccinationAbstract
The paradigm for treating chronic Autoimmune Rheumatic Disorders (ARDs) has changed thanks to biologic disease-modifying anti-rheumatic medicines (bDMARDs), however one of its most significant adverse effects is an elevated risk of infections. The current research assessed the incidence, severity, and type of infections in ARD patients on bDMARDs. Disease activity is interwoven with both infectious and chronic inflammatory diseases. Infections are more likely to occur in people with Rheumatoid Arthritis as high disease activity actually reflects persistent inflammation, which may weaken immunity and encourage the spread of various types of infections. Those with RA had an adjusted risk of being hospitalized with an infection that was two times greater when age, sex, concomitant conditions, and prescription medication use were taken into consideration. The risk of mycobacterial infection appears to be lowest with Etanercept (ETN) and highest with Adalimumab (ADA) and Infliximab (INF). Centers of Disease Control and Prevention (CDC) recommends administration of shingles vaccine to all individuals who are on Tumor Necrosis Factor (TNF) inhibitors to prevent Skin and Soft Tissue Infections (SSTI).
References
Pap, M., Sapina, I., Laktašić Žerjavić, N., et al. (2021). Anti-TNF Therapy and the Risk of Malignancies and Infections in Inflammatory Rheumatic Diseases -Our Experience. Psychiatria Danubina, 33(Suppl 4), 625–631.
Wasson, N. J., Varley, C. D., Schwab, P., Fu, R., & Winthrop, K. L. (2013). "Serious skin & soft tissue infections in rheumatoid arthritis patients taking anti-tumor necrosis factor alpha drugs: a nested case-control study". BMC infectious diseases, 13, 533. https://doi.org/10.1186/1471-2334-13-533
Chiu, Y.-M., Lang, H.-C., Lin, H.-Y., et al. (2014), Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan. Int J Rheum Dis, 17: 9-19. https://doi.org/10.1111/1756-185X.12539
Downey, C. (2016), Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review. Int J Rheum Dis, 19: 536-550. https://doi.org/10.1111/1756-185X.12659
Singh J. A. (2016). Infections With Biologics in Rheumatoid Arthritis and Related Conditions: a Scoping Review of Serious or Hospitalized Infections in Observational Studies. Current rheumatology reports, 18(10), 61. https://doi.org/10.1007/s11926-016-0609-5
Atzeni, F., Gianturco, L., Talotta, R., Varisco, V., Ditto, M. C., Turiel, M., & Sarzi-Puttini, P. (2015). Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: cause for concern?. Immunotherapy, 7(4), 353–361. https://doi.org/10.2217/imt.15.4
Chandrashekara, S., Shobha, V., Rao, V., et al. (2019). Incidence of infection other than tuberculosis in patients with autoimmune rheumatic diseases treated with bDMARDs: a real-time clinical experience from India. Rheumatology international, 39(3), 497–507. https://doi.org/10.1007/s00296-019-04245-4
Kisacik, B., Pamuk, O. N., Onat, A. M., et al. (2016). Characteristics Predicting Tuberculosis Risk under Tumor Necrosis Factor-α Inhibitors: Report from a Large Multicenter Cohort with High Background Prevalence. The Journal of rheumatology, 43(3), 524–529. https://doi.org/10.3899/jrheum.150177
Sakai, R., Komano, Y., Tanaka, M., et al., … Real Study Group (2012). Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis. Arthritis care & research, 64(8), 1125–1134. https://doi.org/10.1002/acr.21666
Curtis, J. R., Xie, F., Chen, L., et al. (2012). Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients. Arthritis care & research, 64(10), 1480–1489. https://doi.org/10.1002/acr.21805
Liao, H., Zhong, Z., Liu, Z., & Zou, X. (2017). Comparison of the risk of infections in different anti-TNF agents: a meta-analysis. International journal of rheumatic diseases, 20(2), 161–168. https://doi.org/10.1111/1756-185X.12970
Chiu, Y. M., & Chen, D. Y. (2020). Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expert review of clinical immunology, 16(2), 207–228. https://doi.org/10.1080/1744666X.2019.1705785
Germano, V., Cattaruzza, M. S., Osborn, J., Tarantino, A., Di Rosa, R., Salemi, S., & D'Amelio, R. (2014). Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-α antagonists. Journal of translational medicine, 12, 77. https://doi.org/10.1186/1479-5876-12-77
Y Wu & B P Zhou. (2010). TNF-α/NF-κB/Snail pathway in cancer cell migration and invasion. British Journal of Cancer, 102, 639–644. https://www.nature.com/articles/6605530
Goel, N., Torralba, K., Downey, C., & Salto, L. (2020). Screening for acquired latent tuberculosis in rheumatoid arthritis patients on tumor necrosis factor inhibition therapy in Southern California. Clinical rheumatology, 39(8), 2291–2297. https://doi.org/10.1007/s10067-020-04991-y
Soare, A., Gheorghiu, A. M., Aramă, V., et al. (2018). Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors: a look beyond the baseline tuberculosis screening protocol. Clinical rheumatology, 37(9), 2391–2397. https://doi.org/10.1007/s10067-017-3916-y
Minozzi, S., Bonovas, S., Lytras, T., et al. (2016). Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert opinion on drug safety, 15(sup1), 11–34. https://doi.org/10.1080/14740338.2016.1240783
Brode, S. K., Jamieson, F. B., Ng, R., et al. (2015). Increased risk of mycobacterial infections associated with anti-rheumatic medications. Thorax, 70(7), 677–682. https://doi.org/10.1136/thoraxjnl-2014-206470
Galloway, J. B., Mercer, L. K., Moseley, A., et al. (2013). Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Annals of the rheumatic diseases, 72(2), 229–234. https://doi.org/10.1136/annrheumdis-2011-201108
Winthrop, K. L., Baddley, J. W., Chen, L., et al. (2013). Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA, 309(9), 887–895. https://doi.org/10.1001/jama.2013.1099
Skalkou, A., Manoli, S. M., Sachinidis, A., et al. (2018). Pyoderma gangrenosum and pyogenic arthritis presenting as severe sepsis in a rheumatoid arthritis patient treated with golimumab. Rheumatology international, 38(1), 161–167. https://doi.org/10.1007/s00296-017-3861-8
Giardina, A. R., Ferraro, D., Ciccia, F., Ferrante, A., Di Stefano, R., Craxì, A., & Triolo, G. (2013). No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study. Clinical and experimental rheumatology, 31(1), 25–30.
Lee, Y. H., Bae, S. C., & Song, G. G. (2013). Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clinical and experimental rheumatology, 31(1), 118–121.
Aikawa, N. E., Rosa, D. T., Del Negro, G. M., et al. (2016). Systemic and localized infection by Candida species in patients with rheumatic diseases receiving anti-TNF therapy. Revista brasileira de reumatologia, 56(6), 478–482. https://doi.org/10.1016/j.rbre.2015.08.004
Cavazzana, I., Taraborelli, M., Fredi, M., Tincani, A., & Franceschini, F. (2014). Aseptic meningitis occurring during anti-TNF-alpha therapy in rheumatoid arthritis and ankylosing spondylitis. Clinical and experimental rheumatology, 32(5), 732–734.
Liang, S. J., Zheng, Q. Y., Yang, Y. L., Yang, Y., & Liu, C. Y. (2017). Use of etanercept to treat rheumatoid arthritis in an HIV-positive patient: a case-based review. Rheumatology international, 37(7), 1207–1212. https://doi.org/10.1007/s00296-017-3690-9
